Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. - Wikidata - wikimedia - TriplyDB

Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

http://www.wikidata.org/entity/Q34075820

about

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.comets (Constrained Optimization of Multistate Energies by Tree Search): A Provable and Efficient Protein Design Algorithm to Optimize Binding Affinity and Specificity with Respect to Sequence.LUTE (Local Unpruned Tuple Expansion): Accurate Continuously Flexible Protein Design with General Energy Functions and Rigid Rotamer-Like Efficiency.Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Germlining of the HIV-1 broadly neutralizing antibody domain m36 Antibody engineering for increased potency, breadth and half-life.Strategies to guide the antibody affinity maturation process A critical question for HIV vaccine development: which antibodies to induce?Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.A critical analysis of computational protein design with sparse residue interaction graphs.HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.BWM*: A Novel, Provable, Ensemble-based Dynamic Programming Algorithm for Sparse Approximations of Computational Protein Design.Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Germline-targeting immunogens.OSPREY Predicts Resistance Mutations Using Positive and Negative Computational Protein Design.Algorithms for protein design.Genetic and structural analyses of affinity maturation in the humoral response to HIV-1.Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.cOSPREY: A Cloud-Based Distributed Algorithm for Large-Scale Computational Protein Design.Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?Fast gap-free enumeration of conformations and sequences for protein design.CATS (Coordinates of Atoms by Taylor Series): protein design with backbone flexibility in all locally feasible directions.BBK* (Branch and Bound Over K*): A Provable and Efficient Ensemble-Based Protein Design Algorithm to Optimize Stability and Binding Affinity Over Large Sequence Spaces.Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.Display of the HIV envelope protein at the yeast cell surface for immunogen development Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design

P2860

Q27644646-612F67B8-F9CF-4BBA-974F-75E6B627988F Q27723297-84EFFEFB-4BDA-4958-8E4C-0B39118D397A Q30234773-75DB78CC-E897-4B92-8EF8-D108EFB83F15 Q30383489-7EEA975C-075B-4C5C-A2BA-7BE808D44887 Q30393514-A9C37334-3CF3-47E7-9AA7-8048924078A7 Q34022578-A1D3D813-B2E7-4647-B67A-AE0FDAC5C0C4 Q34531219-DB3EF065-7B2C-4128-A7A0-0E04B3D3F871 Q34593860-A798DA82-1F36-4BD1-810C-C4FB047A261D Q35171173-35E64279-2548-44CF-B343-19D7B4BCA5DD Q35575206-2A5B4062-850D-4184-88A2-CE5984B0119C Q35685300-62E29FFD-1C85-4C38-8F3F-D6BC7E14F08C Q35783015-AEA11226-7A78-498B-A99D-5F96B1B4335A Q35914292-FD1CAFC1-66A1-4CC6-A889-1FE2085D0B99 Q36112751-C8A8CCE6-8B22-45D3-BD4F-75958DE5260A Q36328057-61A26001-B7CC-4446-94AF-07E9133B0D81 Q36345558-14BBF0AA-B731-4996-B9BC-FE8976915903 Q36996055-E55FF200-D80B-4721-B2E8-B8E74C4A55B4 Q37246321-2D110D96-8918-460F-9A3D-5D5D10D82860 Q37293480-312CBAAD-17C7-4C67-A358-B2846A32CAA3 Q38589314-7BFBFADF-ACD9-40FE-9EFE-1060EAAA26BF Q38717198-413FE7C3-0F2D-4F67-9C75-015A4865F299 Q38764547-67E725F4-0B4F-4E2D-B84D-2DF9EDDA3B8E Q38787688-4A372D34-9984-4A92-9880-746D0B75AB74 Q38810159-30F1C9F8-9780-4DF6-8A00-EA27860632DA Q38992744-28CDDFAE-D798-426C-812E-9F6E68CD0BA2 Q39108735-37B47880-B489-4AD1-8CB4-B5E39427185E Q41626450-68A68B88-FA42-4EEA-8823-4204C3CD72B4 Q41930052-09966FCE-1A91-45CF-B5E1-B3B11A2B9C21 Q41938263-121FD7FD-85F1-43D6-B41F-3B0221803329 Q42695246-706AFB7C-1BFA-4EA0-B79F-08881FA9CC3C Q42697203-69BFDA71-3636-4A5D-9CED-0BD4084B0E74 Q52594333-8819C48B-FCA4-43A8-832A-F965580C2F6C Q55356257-9B88A457-4009-4A7A-BC05-C1CDE4DD3935 Q58601813-48FF37C1-4A44-408D-BA91-B3E4812B5FAE Q58763247-EF5EDDD6-6285-4D19-8A02-22C40066583B Q58781552-5F55293C-210E-4077-B7B6-9A05D94B2AB5

P2860

Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

http://www.wikidata.org/entity/Q34075820

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@ast

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@en

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@nl

type

label

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@ast

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@en

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@nl

prefLabel

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@ast

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@en

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@nl

P1433

Q34075820-3323C166-3D96-4178-81EE-8B7606E38ADE

P1476

Q34075820-DD459518-1BBC-4722-A6B2-7A43301158FE

P2093

Q34075820-15ABDBEF-2DD4-455E-B348-B84D6F2B5FCB

Q34075820-3F0595F7-29EC-43B5-94FD-214FF95DCA78

Q34075820-4B7D3900-7A01-4160-94F4-C7DEF5E0C12F

Q34075820-53BBA692-9C89-4950-A6D8-C78DB0565F8F

Q34075820-6A409DB7-F0B4-4C32-B098-E22175B79674

Q34075820-7D004EC0-3C72-4317-97C0-8578F60B3C9E

Q34075820-93980B4F-8FB8-4739-BA65-CACB00CEE1F4

Q34075820-9D18417F-9947-4FB0-BFAE-5737B7DBAB81

Q34075820-9D4BBCA1-90C7-4E09-BBAA-EA89FCD7B9F5

Q34075820-B13EA5A7-FB93-4132-B61C-E96B17628332

P2860

Q34075820-14790EFD-4AFD-4018-A319-B54CB8AEFBFC

Q34075820-168E3CBD-F6AF-4595-9D91-0971C25CD9C9

Q34075820-1E205C41-9F38-484F-8BA9-F5A727456744

Q34075820-2177D582-073B-4A60-A9CD-842E7C597B8A

Q34075820-26447D48-C1B5-49B0-998E-4AE93868B9CB

Q34075820-408FBF4D-60A6-4920-8D7F-0333D2C12983

Q34075820-4360C39F-5B86-4A06-B624-333C8E009436

Q34075820-487FE49A-667E-4D0A-B446-538792409AE3

Q34075820-52616CE7-CA38-4C9B-8D63-A70F2EC82B66

Q34075820-66085050-9725-4BC6-B62D-17B2B5C73FDB

P304

Q34075820-FC437A64-C1DA-413C-9945-14E7EDC304AB

P31

Q34075820-7E57FF5B-A198-4E64-AEF3-07DCFC69F9C5

P356

Q34075820-7EF948DA-D44D-4645-868B-9A9D4D12EE6D

P407

Q34075820-806E065D-ED5A-4627-94CD-F002686F2580

P433

Q34075820-B6500719-E34E-45AC-A5C7-0C74C52CD9EC

P478

Q34075820-D8E8764B-59F4-4922-9584-68456291C2F1

P50

Q34075820-5920E8BE-A0D3-4A9A-9067-D0768FC35BCE

Q34075820-699F071D-A04D-4FBA-A9C9-7D3365625564

Q34075820-9A2E95AF-903C-42A7-9350-3F0106C26AEE

P577

Q34075820-92E2A791-CB89-4DD2-9B49-09C0434C77E9

P5875

Q34075820-5A3B9854-C2BA-44A3-83E7-9B314E69D41F

P698

Q34075820-D1469264-9D86-4247-92B3-D71CEEC70EDE

P921

Q34075820-490A9233-0272-46F1-BD52-0506DFE7E386

P932

Q34075820-57380E75-063D-44C0-8FCA-4A0E044952F6

P356

JIMMUNOL.1302515

P1433

Journal of Immunology

P1476

Antibodies VRC01 and 10E8 neut ...... antially reverted to germline.

@en

P2093

Gilad Ofek

http://www.w3.org/2001/XMLSchema#string

Gwo-Yu Chuang

http://www.w3.org/2001/XMLSchema#string

Ivelin S Georgiev

http://www.w3.org/2001/XMLSchema#string

Kevin O Saunders

http://www.w3.org/2001/XMLSchema#string

Krisha McKee

http://www.w3.org/2001/XMLSchema#string

Mark Connors

http://www.w3.org/2001/XMLSchema#string

Peter D Kwong

http://www.w3.org/2001/XMLSchema#string

Rebecca S Rudicell

http://www.w3.org/2001/XMLSchema#string

Sijy O'Dell

http://www.w3.org/2001/XMLSchema#string

Tatsiana Kirys

http://www.w3.org/2001/XMLSchema#string

P2860

MolProbity: all-atom structure validation for macromolecular crystallography

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies

P304

1100-1106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1302515

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

192

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259588661

http://www.w3.org/2001/XMLSchema#string

P698

24391217

http://www.w3.org/2001/XMLSchema#string

P921

P932

4140862

http://www.w3.org/2001/XMLSchema#string